Enzo Biochem is a life sciences reagents and tools company operating under its Enzo Life Sciences segment. Enzo sells a broad catalog of consumable research products — including antibodies, genomic probes, assays, biochemicals, dyes, and proteins — that scientists use to label, detect, and visualize biological targets such as DNA, RNA, proteins, and cells. Customers include academic researchers, biotech and pharma companies, and diagnostic manufacturers. Enzo sells directly to end users in the U.S. and several European markets, through Axxora (an online marketplace aggregating products from over 45 specialty manufacturers), supply agreements, and a network of third-party distributors. Because the products are consumables used up during experiments, customers reorder regularly, creating a recurring revenue dynamic. Enzo also monetizes its IP through licensing agreements. Margins are supported by in-house manufacturing at its Farmingdale, New York facility, and a proprietary product portfolio validated across over 160,000 scientific publications. Enzo previously operated a clinical laboratory business, but sold those assets to Labcorp in July 2023 for $113.25M, making Enzo a pure-play life sciences products business. Going forward, Enzo's strategy centers on organic growth — developing new products in areas like spatial biology, cell and gene therapy, and cancer research, expanding its AMPIVIEW in situ hybridization platform, and growing the Axxora marketplace.